Myocardial Fibrosis Progression in Duchenne and Becker Muscular Dystrophy – ACE Inhibitor Therapy Trial
July 8, 2022
Related
Gamida Cell Cuts Workforce, Discontinues Programs as it Awaits Potential FDA Approval
Rare Daily Staff Gamida Cell revealed a strategic restructuring to prioritize the potential approval and launch of […]
Read moreBlind Chef Uses Visibility to Advocate for Rare Disease
Christine Ha taught herself to cook while in college. As a finance student at the University of […]
Read moreFDA Issues Says It Won’t Approve Incyte’s Ruxolitinib Extended Release Tablets to Treat Rare Blood Disorders
Rare Daily Staff The U.S. Food and Drug Administration has issued to Incyte a complete response letter […]
Read moreAddressing the Barriers to Patient Participation in Clinical Trials
A significant obstacle to getting patients to participate in rare disease clinical trials, particularly children, is the […]
Read moreGovernment of Canada Improves Access to Affordable and Effective Drugs for Rare Diseases
Rare Daily Staff The Canadian government said it would invest $1.1 billion (CAN$1.5 billion) over three years […]
Read moreModerna and Generation Bio Enter Strategic Collaboration to Develop Non-Viral Genetic Medicines
Rare Daily Staff Messenger RNA pioneer Moderna has entered into a strategic collaboration with genetic medicines developer […]
Read moreFDA Approves Incyte’s Zynyz for the Treatment of Rare Cancer
Rare Daily Staff The U.S. Food and Drug Administration has approved Incyte’s Zynyz, a humanized monoclonal antibody […]
Read moreFDA Grants Orphan Drug and Rare Pediatric Designations for Dyne’s Treatment for Duchenne Muscular Dystrophy
Rare Daily Staff The U.S. Food and Drug Administration has granted orphan drug and rare pediatric disease […]
Read moreAcer Therapeutics Raises $2.7 Million in Registered Direct Offering Priced At-the-Market
Rare Daily Staff Rare disease drug developer Acer Therapeutics said it is raising $2.675 million in a […]
Read more